Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Schizophrenic symptoms improve with apomorphine.

C A Tamminga, M H Schaffer, R C Smith

    Science (New York, N.Y.)
    |May 5, 1978
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Corrigendum to "Jang YJ, et al. Characterizing the relationship between personality dimensions and psychosis-specific clinical characteristics" [Schizophr Res. 276 (2025) 88-96 10.1016/j.schres.2025.01.002 (Epub ahead of print, PMID: 39864301, Jan 25)].

    Schizophrenia research·2025
    Same author

    Emotional scene processing in biotypes of psychosis.

    Psychiatry research·2023
    Same author

    VGF function in depression and antidepressant efficacy.

    Molecular psychiatry·2017
    Same author

    Genome-wide association studies of smooth pursuit and antisaccade eye movements in psychotic disorders: findings from the B-SNIP study.

    Translational psychiatry·2017
    Same author

    Deviation from expected cognitive ability across psychotic disorders.

    Schizophrenia research·2017
    Same author

    Unitary construct of generalized cognitive ability underlying BACS performance across psychotic disorders and in their first-degree relatives.

    Schizophrenia research·2015
    Same journal

    Erratum for the Research Article "Detecting supramolecular organic nanoparticles during heat wave".

    Science (New York, N.Y.)·2026
    Same journal

    Local signals, systemic decline.

    Science (New York, N.Y.)·2026
    Same journal

    The mechanics of liver regeneration.

    Science (New York, N.Y.)·2026
    Same journal

    Computing in a memory with physics.

    Science (New York, N.Y.)·2026
    Same journal

    Retraction.

    Science (New York, N.Y.)·2026
    Same journal

    Making time.

    Science (New York, N.Y.)·2026
    See all related articles

    Apomorphine, a dopamine receptor agonist, significantly improved psychotic symptoms in chronic schizophrenic patients compared to placebo. This suggests apomorphine may reduce dopamine-mediated neural transmission by activating presynaptic receptors.

    Area of Science:

    • Neuroscience
    • Psychiatry
    • Pharmacology

    Background:

    • Schizophrenia is a chronic mental disorder characterized by psychosis.
    • Dopamine pathways are implicated in the pathophysiology of schizophrenia.

    Purpose of the Study:

    • To investigate the efficacy of apomorphine, a dopamine receptor agonist, in treating psychotic symptoms of chronic schizophrenia.
    • To explore the potential mechanism of action of apomorphine in schizophrenia.

    Main Methods:

    • Eighteen patients with chronic schizophrenia participated in a double-blind, placebo-controlled study.
    • Patients received subcutaneous doses of apomorphine and placebo in separate trials.

    Main Results:

    • Apomorphine administration led to a significant improvement in psychotic symptoms compared to placebo.

    Related Experiment Videos

  • No adverse events were reported.

    • Conclusions:

    • Apomorphine demonstrates therapeutic potential for alleviating psychotic symptoms in chronic schizophrenia.
    • The findings support the hypothesis that presynaptic dopamine receptor activation by apomorphine reduces dopamine-mediated neural transmission.